Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Racial and ethnic disparities in post-stroke blood pressure (BP) control persist, and effective interventions to address post-stroke care inequities are needed. We designed a randomized comparative effectiveness trial to evaluate the Video-based Intervention to Reduce Treatment and Outcome Disparities in Adults Living with Stroke or Transient Ischemic Attack (VIRTUAL) model of care for post-stroke BP reduction.

Methods: The study will enroll 534 stroke survivors in a randomized trial to receive either the VIRTUAL intervention or enhanced standard care. Individuals with ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA) are enrolled before hospital discharge and randomized (1:1) to VIRTUAL or ESC for their post-stroke care. The VIRTUAL care model is a social risk-informed telehealth intervention that incorporates remote BP monitoring and multidisciplinary clinical care from a clinical provider, pharmacist, and social worker. Telehealth (TH) based clinical visits occur 7, 30, 90, and 150 days after hospital discharge with the multidisciplinary care team. Pharmacists monitor and manage BP between telehealth visits for 6 months after enrollment. Patients randomized to ESC receive standard post-stroke follow-up, a BP monitor (without remote capabilities), and pharmacist-engaged care (monthly calls and communication to primary care). The primary outcome is BP control (< 125/75 mmHg) assessed with 24-h ambulatory BP monitoring (ABPM) 6 months after hospital discharge. The secondary outcomes are 24-h ABPM-assessed BP control (< 125/75 mmHg) at 12 months, 6- and 12-month mean systolic and diastolic ambulatory BP, 12-month composite recurrent vascular events, insurance coverage at 3 and 6 months, hospital readmission rates, and acute healthcare utilization (emergency room and urgent care visits) at 3, 6, and 12 months after hospital discharge.

Discussion: The VIRTUAL care model represents a novel approach to addressing post-stroke BP control disparities. The intervention aims to improve BP control and reduce disparities in a diverse patient population by integrating telehealth with a multidisciplinary team approach and social risk-informed care. Findings from this study will inform evidence-based strategies for enhancing post-stroke care delivery, particularly in underserved populations, and may contribute to reducing healthcare disparities among racial and ethnic groups.

Trial Registration: ClinicalTrials.gov. NCT05264298. Registered on March 3, 2022. URL of trial registry record: https://clinicaltrials.gov/study/NCT05264298?cond=stroke&term=virtual%20&rank=2 .

Trial Status: Protocol version 1.5, approved May 15, 2024. Recruitment started on March 29, 2022, and was completed on April 28, 2025.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344908PMC
http://dx.doi.org/10.1186/s13063-025-09003-5DOI Listing

Publication Analysis

Top Keywords

stroke transient
12
transient ischemic
12
ischemic attack
12
care
9
video-based intervention
8
intervention reduce
8
reduce treatment
8
treatment outcome
8
outcome disparities
8
disparities adults
8

Similar Publications

Timing Matters: How Daily Rhythms Affect Remote Ischemic Postconditioning Therapy for Stroke.

Stroke

September 2025

Departments of Radiology and Neurology, Neuroprotection Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston (E.L., R.M.P., K.H., E.H.L., E.E.).

Background: Despite promising preclinical results, remote limb ischemic postconditioning efficacy in human stroke treatment remains unclear, with mixed clinical trial outcomes. A potential reason for translational difficulties could be differences in circadian rhythms between nocturnal rodent models and diurnal humans.

Methods: Male C57BL/6J mice were subjected to transient focal cerebral ischemia and then exposed to remote postconditioning during their active or inactive phase and euthanized at 24 hours and 3 days.

View Article and Find Full Text PDF

Repopulating Microglia Suppress Peripheral Immune Cell Infiltration to Promote Poststroke Recovery.

CNS Neurosci Ther

September 2025

Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Aims: Sustained neuroinflammation following ischemic stroke impedes post-injury tissue repairment and neurological functional recovery. Developing innovative therapeutic strategies that simultaneously suppress detrimental inflammatory cascades and facilitate neurorestorative processes is critical for improving long-term rehabilitation outcomes.

Methods: We employed a microglia depletion-repopulation paradigm by administering PLX5622 for 7 days post-ischemia; followed by a 7-day withdrawal period to allow microglia repopulation.

View Article and Find Full Text PDF

Background: In Vietnam, the incidence of transient ischemic attack (TIA) or ischemic stroke has increased in recent years due to lifestyle changes. Carotid stenosis is a common cause of TIA/ischemic stroke. This study aimed to determine the prevalence and identify risk factors for ipsilateral internal carotid artery (ICA) stenosis in patients with transient ischemic attack (TIA) or ischemic stroke.

View Article and Find Full Text PDF

Takotsubo Cardiomyopathy (TC) is a transient cardiomyopathy secondary to emotional and/or physical stress. While its precise aetiology remains unclear, some evidence suggests a possible role for the insular cortex (IC), which modulates cardiovascular responses to stress. The IC is a key viscerosensory and visceromotor hub with widespread connections, and is implicated in interoceptive processing, emotional regulation, and autonomic control.

View Article and Find Full Text PDF

Background: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain.

Methods: CHANCE-2 (Clopidogrel in High-Risk Patients With Acute Non-disabling Cerebrovascular Events-II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles.

View Article and Find Full Text PDF